Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Not yet recruiting · NCT06845241 · Registry updated 2025-02-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2025-02-25 | NCT06845241 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing InnoCare Pharma Tech Co., Ltd. | 26 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fujian Cancer Hospital | Fuzhou | China | 109 |
| Henan Cancer Hosptital | Zhengzhou | China | 1 |
| Sun Yat-sen University Cancer Center | Guangzhou | China | 61 |
| The First Affiliated Hospital of Nanchang University | Nanchang | China | 18 |
| The Second Affiliated Hospital of Kunming Medical University | Kunming | China | 5 |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin | China | 20 |